» Articles » PMID: 37508204

Risk Factors Associated with the Development of Hospital-Acquired Infections in Hospitalized Patients with Severe COVID-19

Abstract

Recognition of risk factors for hospital-acquired infections (HAI) in patients with COVID-19 is warranted. We aimed to describe factors associated with the development of HAI in patients with severe COVID-19. We conducted a retrospective cohort study including all adult patients admitted with severe COVID-19 between March 2020 and November 2020. The primary outcome was HAI development. Bivariate and multiple logistic regression models were constructed. Among 1540 patients, HAI occurred in 221 (14%). A total of 299 episodes of HAI were registered. The most common HAI were hospital-acquired/ventilation-associated pneumonia (173 episodes) and primary bloodstream infection (66 episodes). Death occurred in 387 (35%) patients and was more frequent in patients with HAI (38% vs. 23%, < 0.01). Early mechanical ventilation (aOR 18.78, 95% CI 12.56-28.07), chronic kidney disease (aOR 3.41, 95% CI 1.4-8.27), use of corticosteroids (aOR 2.95, 95% CI 1.92-4.53) and tocilizumab (aOR 2.68, 95% CI 1.38-5.22), age ≥ 60 years (aOR 1.91, 95% CI 1.27-2.88), male sex (aOR 1.52, 95% CI 1.03-2.24), and obesity (aOR 1.49, 95% CI 1.03-2.15) were associated with HAI. In patients with severe COVID-19, mechanical ventilation within the first 24 h upon admission, chronic kidney disease, use of corticosteroids, use of tocilizumab, age ≥ 60 years, male sex, and obesity were associated with a higher risk of HAI.

Citing Articles

The impact of the COVID-19 pandemic on pediatric bloodstream infections and alteration in antimicrobial resistance phenotypes in Gram-positive bacteria, 2020-2022.

Fallah F, Karimi A, Azimi L, Ghandchi G, Gholinejad Z, Abdollahi N BMC Pediatr. 2024; 24(1):671.

PMID: 39425109 PMC: 11487802. DOI: 10.1186/s12887-024-05146-7.

References
1.
Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

2.
Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

3.
Grasselli G, Scaravilli V, Mangioni D, Scudeller L, Alagna L, Bartoletti M . Hospital-Acquired Infections in Critically Ill Patients With COVID-19. Chest. 2021; 160(2):454-465. PMC: 8056844. DOI: 10.1016/j.chest.2021.04.002. View

4.
Martinez-Guerra B, Gonzalez-Lara M, de-Leon-Cividanes N, Tamez-Torres K, Roman-Montes C, Rajme-Lopez S . Antimicrobial Resistance Patterns and Antibiotic Use during Hospital Conversion in the COVID-19 Pandemic. Antibiotics (Basel). 2021; 10(2). PMC: 7917840. DOI: 10.3390/antibiotics10020182. View

5.
De Bruyn A, Verellen S, Bruckers L, Geebelen L, Callebaut I, De Pauw I . Secondary infection in COVID-19 critically ill patients: a retrospective single-center evaluation. BMC Infect Dis. 2022; 22(1):207. PMC: 8890021. DOI: 10.1186/s12879-022-07192-x. View